A Phase 1 interventional study of Sotorasib in Hepatic Impairment, sponsored by Amgen. Completed at 5 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-19.
Sponsored by Amgen · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of the study is to evaluate the pharmacokinetics (PK) of a single oral dose of sotorasib administered in participants with moderate or severe hepatic impairment compared to participants with normal hepatic function.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria
All Participants
Participants with Normal Hepatic Function
Participants with Hepatic Impairment
Key Exclusion Criteria
All Participants
Participants with Normal Hepatic Function
Participants with Hepatic Impairment
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Sotorasib
Drug: Sotorasib
Drug: Sotorasib
Sotorasib will be administered as an oral tablet.
Also known as: AMG 510
Maximum Observed Plasma Concentration (Cmax) of Sotorasib
Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose following administration of sotorasib on Day 1
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of Sotorasib
Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose following administration of sotorasib on Day 1
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of Sotorasib
Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose following administration of sotorasib on Day 1
Number of Participants Who Experienced One or More Treatment Emergent Adverse Events (TEAEs)
TEAEs were defined as any adverse events (AEs) that started during or after dosing, or started prior to dosing and increased in severity after dosing. Any clinically significant changes in clinical laboratory evaluations, 12-lead electrocardiograms (ECGs) and vital signs were also reported as TEAEs.
Time frame: Day 1 to Day 8
Unbound Cmax (Cmax,u) of Sotorasib
Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose following administration of sotorasib on Day 1
Unbound AUClast (AUClast,u) of Sotorasib
Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose following administration of sotorasib on Day 1
Unbound AUCinf (AUCinf,u) of Sotorasib
Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose following administration of sotorasib on Day 1
Unbound Apparent Total Plasma Clearance (CLu/F) of Sotorasib
Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose following administration of sotorasib on Day 1
Unbound Apparent Volume of Distribution During the Terminal Phase (Vz,u/F) of Sotorasib
Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose following administration of sotorasib on Day 1
Participants were enrolled at research centers in the United States from April 2021 to March 2022.
| Milestone | Normal Hepatic Function | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|
| Started | 7 | 8 | 5 |
| Completed | 7 | 8 | 5 |
| Not completed | 0 | 0 | 0 |
| ng/mL | Normal Hepatic Function | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Sotorasib | 5080 ± 108.5 | 4850 ± 60.6 | 7250 ± 15.7 |
| h*ng/mL | Normal Hepatic Function | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of Sotorasib | 28700 ± 87.8 | 21500 ± 58.2 | 29900 ± 12.6 |
| h*ng/mL | Normal Hepatic Function | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of Sotorasib | 29000 ± 86.4 | 21700 ± 58.2 | 30100 ± 12.2 |
TEAEs were defined as any adverse events (AEs) that started during or after dosing, or started prior to dosing and increased in severity after dosing. Any clinically significant changes in clinical laboratory evaluations, 12-lead electrocardiograms (ECGs) and vital signs were also reported as TEAEs.
| Participants | Normal Hepatic Function | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|
| Number of Participants Who Experienced One or More Treatment Emergent Adverse Events (TEAEs) | 1 | 2 | 1 |
| ng/mL | Normal Hepatic Function | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|
| Unbound Cmax (Cmax,u) of Sotorasib | 183 ± 240.8 | 400 ± 110.9 | 1220 ± 9.8 |
| h*ng/mL | Normal Hepatic Function | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|
| Unbound AUClast (AUClast,u) of Sotorasib | 694 ± 146.3 | 1320 ± 71.0 | 4680 ± 29.4 |
| h*ng/mL | Normal Hepatic Function | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|
| Unbound AUCinf (AUCinf,u) of Sotorasib | 742 ± 156.7 | 1340 ± 69.6 | 4680 ± 29.4 |
| L/h | Normal Hepatic Function | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|
| Unbound Apparent Total Plasma Clearance (CLu/F) of Sotorasib | 1290 ± 156.7 | 715 ± 69.6 | 205 ± 29.4 |
| liters | Normal Hepatic Function | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|
| Unbound Apparent Volume of Distribution During the Terminal Phase (Vz,u/F) of Sotorasib | 7080 ± 275.6 | 3820 ± 115.2 | 928 ± 39.1 |
Collected over Day 1 to Day 8. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Normal Hepatic Function | 0/7 (0%) | 0/7 (0%) | 1/7 (14.3%) |
| Moderate Hepatic Impairment | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Severe Hepatic Impairment | 0/5 (0%) | 0/5 (0%) | 1/5 (20%) |
| Event | Normal Hepatic Function | Moderate Hepatic Impairment | Severe Hepatic Impairment |
|---|---|---|---|
| Electrocardiogram qt prolongedInvestigations | 0/7 | 0/8 | 1/5 |
| RashSkin and subcutaneous tissue disorders | 0/7 | 0/8 | 1/5 |
| ConstipationGastrointestinal disorders | 1/7 | 0/8 | 0/5 |
| Abdominal distensionGastrointestinal disorders | 0/7 | 1/8 | 0/5 |
| DiarrhoeaGastrointestinal disorders | 0/7 | 1/8 | 0/5 |
| Dry mouthGastrointestinal disorders | 0/7 | 1/8 | 0/5 |
| NauseaGastrointestinal disorders | 0/7 | 1/8 | 0/5 |
| ContusionInjury, poisoning and procedural complications | 0/7 | 1/8 | 0/5 |
| Sensory disturbanceNervous system disorders | 0/7 | 1/8 | 0/5 |
Safety Population: All participants who received sotorasib and had at least 1 postdose safety assessment.
| Age, Continuous(years) | Normal Hepatic Function | Moderate Hepatic Impairment | Severe Hepatic Impairment | Total |
|---|---|---|---|---|
| Mean | 59.0 ± 7.35 | 58.5 ± 5.66 | 51.6 ± 7.37 | 57.0 ± 7.10 |
| Sex: Female, Male(Participants) | Normal Hepatic Function | Moderate Hepatic Impairment | Severe Hepatic Impairment | Total |
|---|---|---|---|---|
| Female | 3 | 4 | 2 | 9 |
| Male | 4 | 4 | 3 | 11 |
| Ethnicity (NIH/OMB)(Participants) | Normal Hepatic Function | Moderate Hepatic Impairment | Severe Hepatic Impairment | Total |
|---|---|---|---|---|
| Hispanic or Latino | 4 | 6 | 3 | 13 |
| Not Hispanic or Latino | 3 | 2 | 2 | 7 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Normal Hepatic Function | Moderate Hepatic Impairment | Severe Hepatic Impairment | Total |
|---|---|---|---|---|
| White | 6 | 8 | 4 | 18 |
| Black or African American | 1 | 0 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Apr 2021 to primary completion in Mar 2022, 10 months.
Results were first posted in Apr 2024, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sotorasib